Loading…
Company states no further financings planned for 2026.
Lexaria Bioscience Corp. announced Lexaria Bioscience announced that an Australian tax refund and institutional financing priced at $12.92 per share yielded $7.9 million net, about $4.60 per share in cash on 2.1 million shares outstanding; the company also stated that no further financings are planned in 2026.
The announcement cited $7.9M, $12.92/share, $4.60/share, and 2.1 million shares. Share consideration (with the issuer receiving shares): 2.1 million shares.
Lexaria Bioscience Corp. has a free float of 1,602,575 shares and 1,652,518 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.